Last reviewed · How we verify
NCT05667948
Molecular Analysis and Treatment Options of Thymic Malignancies
trial testing Chemotherapy in Thymic Epithelial Tumor in 500 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Shanghai Chest Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 January 2016 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Chemotherapy (chemotherapy) — full drug profile →
Conditions studied
- Thymic Epithelial Tumor — all drugs for Thymic Epithelial Tumor →
- Thymic Carcinoma — all drugs for Thymic Carcinoma →
- Thymic Cancer — all drugs for Thymic Cancer →
Sponsor
Shanghai Chest Hospital
Who can join
18 and older, any sex, with Thymic Epithelial Tumor or Thymic Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies. In summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Comparative Analysis of Comprehensive Genomic Profile in Thymomas and Recurrent Thymomas Reveals Potentially Actionable Mutations for Target Therapies.
Lococo F, De Paolis E, Evangelista J, Dell'Amore A, et al · · 2024 · cited 2× · PMID 39273507 · DOI 10.3390/ijms25179560
Verify or expand the search:
- PubMed search for NCT05667948
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Chemotherapy
Trials testing the same drug.
- NCT07391774 — Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic · Phase 3 · not yet recruiting
- NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
- NCT07392892 — A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · Phase 2, PHASE3 · recruiting
- NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
- NCT07078604 — A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negati · Phase 2 · recruiting
Other recruiting trials for Thymic Epithelial Tumor
Currently open trials in the same condition.
- NCT06311955 — Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor · Phase 2 · recruiting
- NCT06692062 — Hypofractionated Radiotherapy for Thymic Epithelial Tumors · NA · recruiting
- NCT06301945 — Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors · recruiting
- NCT05104736 — PT-112 in Subjects With Thymoma and Thymic Carcinoma · Phase 2 · recruiting
- NCT04417660 — Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma · Phase 2 · active not recruiting
Other Shanghai Chest Hospital trials
Trials by the same sponsor.
- NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
- NCT07479628 — Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma · Phase 2 · not yet recruiting
- NCT07528066 — Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC · recruiting
- NCT07331727 — Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation · NA · not yet recruiting
- NCT07320768 — Renal Denervation Combined With Pulsed Field Ablation to Prevent Blanking-Period Recurrence in Persistent Atrial Fibrill · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05667948 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Chest Hospital
- Last refreshed: 22 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05667948.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing